论文部分内容阅读
为了观察青蒿琥酯片预防疟疾的效果,1991～1992年选择疟疾高发区——三亚市高峰乡福万水库和电站作为试验压,以户为单位将试验区人口分为青蒿琥酯片试验组和安慰剂对照组,进行对照观察。1992年以1991年分组为基础,两组互相对换服药,增加人员以户为原则分别编入两组内。1991年试验组与对照组人数分别为77人与56人,1992年分别为75人与79人。试验组每周一次口服青蒿琥酯片100mg,1991年连服13周,1992年连服16周。结果:1991年试验组无发病,对照组发病率为8.93％(P<0.01);1992年试验组发病率为4.0％,对照组为13.92％(P<0.05);两年合计发病率试验组为1.97％,对照组为11.85％(P<0.01)。观察结果提示,虽然青蒿琥酯是一个速效而半衰期甚短的抗疟药,但是每周口服100mg对于疟疾的预防有一定的作用,且未发现任何副反应。对于短期进入疟区作业的人群,采用该方案是可行的。
In order to observe the effect of artesunate tablets in preventing malaria, from 1991 to 1992, Fuwan reservoir and power station in Gaofeng Township, Sanya City were selected as the test pressure, and the population in the pilot area was divided into artesunate tablets The experimental group and the placebo control group, the control observation. In 1992, based on the 1991 sub-grouping, the two groups exchanged their medication with each other and the principle of adding people to households was incorporated into each of the two groups. The number of test and control groups in 1991 was 77 and 56 respectively, compared with 75 and 79 in 1992 respectively. Test group once weekly oral artesunate tablets 100mg, 1991 even served 13 weeks in 1992 even served 16 weeks. Results: The incidence of the experimental group in 1991 was 8.93% (P <0.01). The incidence of the experimental group was 4.0% in 1992 and 13.92% in the control group (P <0.05) 1.97% in the control group and 11.85% in the control group (P <0.01). Observations suggest that although artesunate is a fast-acting but short-lived antimalarial, oral administration of 100 mg weekly has some effect on the prevention of malaria and no side effects have been found. For short-term access to people working in areas of malaria, the program is feasible.